Approval of the First Oral PCSK9 Inhibitor and its Clinical Significance

Lipfendra (enlicitide), developed by Merck & Co. (MRK), received official approval from the U.S. Food and Drug Administration (FDA) on July 16, 2026. This approval marks a significant advancement in the treatment of hyperlipidemia, as it introduces the first once-daily oral PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor in a market previously dominated by injectable therapies. Lipfendra is a macrocyclic peptide that directly binds to the PCSK9 protein, blocking its interaction with the low-density lipoprotein receptor (LDLR). In the Phase 3 CORALreef Lipids and CORALreef HeFH trials, Lipfendra demonstrated significant efficacy, reducing LDL cholesterol (LDL-C) by 56% and 59% compared to placebo at week 24.

Challenging Dosage Requirements May Hinder Convenience

The shift from injectable to oral administration represents a significant improvement in the convenience of treatment for patients with high cholesterol. However, to maximize prescription rates and adherence in clinical practice, the unique dosage requirements must be addressed. Patients must maintain an 8-hour fast before taking the medication and wait 30 minutes after taking it before consuming any food. These strict dietary restrictions, requiring administration first thing in the morning, could negatively impact patients' ability to adhere to the prescribed schedule. Therefore, the extent to which Merck provides patient support programs or adherence guides to mitigate these limitations will be a key factor in the drug's market success.

Aggressive Pricing and a Major Restructuring of the Competitive Landscape

Merck has set a list price of $315 per month (30-day supply) for Lipfendra, demonstrating a strong commitment to market penetration. This price is significantly more accessible than existing injectable competitors, such as Amgen's Repatha (evolocumab) and Sanofi and Regeneron's Praluent (alirocumab), which cost thousands of dollars per year. This pricing strategy, combined with the lower cost of synthetic drugs compared to injectable biologics, is intended to facilitate insurance coverage and reduce out-of-pocket costs for patients. Furthermore, it positions Lipfendra favorably against Novartis' Leqvio (inclisiran), which is administered twice a year, and AstraZeneca's AZD0780, an oral PCSK9 inhibitor in Phase 2 development.

Controversy Surrounding Expedited Regulatory Review

The rapid FDA approval of Lipfendra is a notable example of a drug that benefited from the priority review voucher program, which was introduced by former FDA Commissioner Marty Makary to promote public health. While the FDA did not explicitly mention the use of the voucher in its approval announcement, the industry is focused on the significantly shorter review timeline compared to the standard process. While expedited review processes can improve patient access to innovative drugs, concerns remain that the accelerated timelines may not allow for a thorough assessment of long-term safety. As a result, Merck will be required to conduct post-marketing surveillance (PMS) and continue to demonstrate long-term cardiovascular safety data in real-world clinical settings.